Brain Aging and Dysregulated Protein Phosphorylation in Alzheimer Disease
Altered phosphorylation patterns of some proteins may have implications for sporadic Alzheimer disease.
Cognitive Impairment
Dietary Flavonoids May Lower Odds of Subjective Cognitive Decline
Higher dietary intake of flavonoids is associated with lower likelihood of subjective cognitive decline.
Cognitive Impairment Reported After COVID-19 Infection
Cognitive impairment has been reported following recovery from COVID-19, according to two studies presented at the annual Alzheimer’s Association International Conference.
Relationship Between Kawasaki Disease Heterogeneity and Cognitive Development of Patients, Caregiver Stress
Study researchers sought to assess the link between Kawasaki disease and patient cognitive profiles or caregiver parenting stress.
Understanding the Relationship Between Alzheimer Disease and HIV
Study researchers sought to differentiate between HIV-associated neurocognitive disorder and true Alzheimer disease in patients with HIV.
Can Autoantibodies Be Used as Biomarkers for the Diagnosis of Neuropsychiatric Systemic Lupus Erythematosus?
In this review, the author discusses the use of autoantibodies as biomarkers for the differential diagnosis of neuropsychiatric systemic lupus erythematosus.
Cognitive Decline May Be Slower With Blood-Brain Barrier Crossing Antihypertensive Drugs
Researchers assessed the ability of antihypertensive drugs to cross the blood-brain barrier.
Blood-Based Biomarkers May Predict Alzheimer’s Disease Risk
Determining if a patient with subtle cognitive symptoms suffers from prodromal or preclinical Alzheimer disease (AD) and whether that patient will progress to AD dementia is a challenge. However, this determination is critically important in order to ascertain a correct and early diagnosis of AD. Researchers may have found one method that can help.
Functional Impairments Associated With Non-Medical Use of Psychoactive Drugs Among Older Adults
With psychoactive substance use being risky for some adults with functional impairments, this study investigated cannabis use, prescription opioid, and tranquilizer/sedative (mis)use among US adults aged ≥50 years who reported functional impairments.
Donanemab Therapy Modestly Reduces Cognitive and Functional Decline Among Patients With Early Alzheimer Disease
The accumulation of amyloid-β (Aβ) peptide is a sign of Alzheimer disease (AD). The researchers investigated donanemab, an antibody that targets a modified form of deposited Aβ, as a method for treating early AD.
- Loading...
Loading...
Next post in Alzheimer Disease and Dementia
Loading... 
Loading...